Developer docs
API playgroundTry for free, no card

Search company profiles

NaviGate Cardiac Structures

Full company profile

uuid000fymb

Namestring
NaviGate Cardiac Structures
Websiteurl
navigatecsi.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

NaviGate Cardiac Structures is a privately held, for-profit medical device developer founded in 2011 and headquartered in Lake Forest, California, with a reported headcount of 1–10 employees. Per its own short description, the company develops transcatheter solutions for the treatment of tricuspid regurgitation, placing it in the structural heart / transcatheter valve intervention segment adjacent to the broader transcatheter mitral valve market, which third-party data sizes at a projected $2.49 billion by 2030 growing at a 9.0% CAGR.

The company's leadership team is small and disclosed only at the executive level: R.C. Quijano serves as Chief Technology Officer and Peter Hinchliffe serves as President and CEO. No further management, board, scientific advisory, or clinical advisory members are documented in the input. The public-facing website (navigatecsi.com) returned a non-substantive / corrupted scrape in the source data, so no product names, pipeline stages, regulatory filings, study sites, design specifics, or platform architecture can be evidenced from the company's own material at this time.

No revenue model, pricing model, distribution channel, partnership, customer logo, funding round, investor, subsidiary, geographic market served, regulatory milestone, certification, patent, or award is documented in the input. Business model mechanics — how the company intends to monetize (e.g., direct hospital sales, licensing to a strategic, royalty stream following CE mark / FDA approval) — are therefore not stated in the source material. The overall evidentiary base is thin: the company is identifiable and positioned in a real, growing clinical segment, but commercial, financial, and operational specifics are absent.

Short descriptiontext

NaviGate Cardiac Structures is a private Lake Forest, California medical device company (founded 2011, 1–10 employees) developing transcatheter solutions to treat tricuspid regurgitation in the structural heart market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLake Forest, United States
HQ citystring
Lake Forest
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
transcatheter heart valves, tricuspid regurgitation treatment, cardiac structural devices, minimally invasive cardiology, heart valve replacement
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Structural Heart Devices
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NaviGate Cardiac Structures develops transcatheter solutions for the treatment of tricuspid regurgitation. The company focuses on minimally invasive cardiac devices designed to address structural heart disease, specifically targeting the tricuspid valve. Its work sits within the broader transcatheter mitral and tricuspid valve market, which is projected to reach $2.49 billion by 2030 at a 9.0% CAGR.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Transcatheter Tricuspid Valve Solutions
CategoryStructural Heart / Transcatheter Heart Valves
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeBroad incumbent
Description

Diversified medical device major with the TriClip transcatheter tricuspid repair system (formerly from its acquisition of Evalve-adjacent tricuspid assets). Directly comparable as a transcatheter tricuspid competitor with deep clinical, regulatory, and commercial resources.

TypeBroad incumbent
Description

Major structural heart player with transcatheter valve programs across aortic, mitral, and tricuspid indications. Comparable to NaviGate as a transcatheter valve developer with significant R&D infrastructure and global commercial reach.

TypeEmerging player
Description

Italian developer of transcatheter mitral and tricuspid valve replacement technologies (Saturn system). Comparable as an emerging transcatheter valve company targeting tricuspid regurgitation.

TypeEmerging player
Description

Developer of the Carillon mitral contour system, with adjacent transcatheter tricuspid development activity. Comparable as a small-to-mid stage structural heart company developing transcatheter valve/repair technologies for under-treated indications.

TypeBroad incumbent
Description

Global structural heart leader developing transcatheter tricuspid platforms including the EVOQUE and PASCAL systems. Highly comparable as a transcatheter valve developer addressing tricuspid regurgitation, though operating at vastly greater scale and across many cardiovascular indications.

TypeDirect peer
Description

Dublin-based developer of a transcatheter tricuspid coaptation device for treating tricuspid regurgitation. Directly comparable niche player competing in the same transcatheter tricuspid space as NaviGate.

TypeDirect peer
Description

Early-stage transcatheter mitral and tricuspid valve developer (e.g., AltaValve). Highly comparable as a similarly sized, venture-backed company focused on transcatheter solutions for under-served valve indications.

8Venus Medtech
TypeRegional player
Description

China-based structural heart company developing transcatheter valve replacement systems including tricuspid programs. Comparable as a transcatheter valve developer with overlapping technology focus, though primarily serving the China market.

TypeEmerging player
Description

Early-stage developer of transcatheter tricuspid repair technology. Comparable emerging private competitor working on minimally invasive solutions for tricuspid regurgitation.

TypeDirect peer
Description

European developer of the Topaz transcatheter tricuspid valve replacement system. Highly comparable as a similarly focused, similarly small private competitor in the transcatheter tricuspid space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NaviGate Cardiac Structures

Structural Heart Devicesnavigatecsi.com

NaviGate Cardiac Structures is a private Lake Forest, California medical device company (founded 2011, 1–10 employees) developing transcatheter solutions to treat tricuspid regurgitation in the structural heart market.

What NaviGate Cardiac Structures does

NaviGate Cardiac Structures is a privately held, for-profit medical device developer founded in 2011 and headquartered in Lake Forest, California, with a reported headcount of 1–10 employees. Per its own short description, the company develops transcatheter solutions for the treatment of tricuspid regurgitation, placing it in the structural heart / transcatheter valve intervention segment adjacent to the broader transcatheter mitral valve market, which third-party data sizes at a projected $2.49 billion by 2030 growing at a 9.0% CAGR.

The company's leadership team is small and disclosed only at the executive level: R.C. Quijano serves as Chief Technology Officer and Peter Hinchliffe serves as President and CEO. No further management, board, scientific advisory, or clinical advisory members are documented in the input. The public-facing website (navigatecsi.com) returned a non-substantive / corrupted scrape in the source data, so no product names, pipeline stages, regulatory filings, study sites, design specifics, or platform architecture can be evidenced from the company's own material at this time.

No revenue model, pricing model, distribution channel, partnership, customer logo, funding round, investor, subsidiary, geographic market served, regulatory milestone, certification, patent, or award is documented in the input. Business model mechanics — how the company intends to monetize (e.g., direct hospital sales, licensing to a strategic, royalty stream following CE mark / FDA approval) — are therefore not stated in the source material. The overall evidentiary base is thin: the company is identifiable and positioned in a real, growing clinical segment, but commercial, financial, and operational specifics are absent.

NaviGate Cardiac Structures firmographics

Firmographics
Name
NaviGate Cardiac Structures
Website
https://navigatecsi.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
NaviGate Cardiac Structures is a private Lake Forest, California medical device company (founded 2011, 1–10 employees) developing transcatheter solutions to treat tricuspid regurgitation in the structural heart market.
Ownership category
akta.pro rank

NaviGate Cardiac Structures industry classification

Industry
Product category
Structural Heart Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Transcatheter heart valves
  • Tricuspid regurgitation treatment
  • Cardiac structural devices
  • Minimally invasive cardiology
  • Heart valve replacement

Where NaviGate Cardiac Structures is headquartered

Location

Headquarters

HQ city
Lake Forest
HQ country
United States
HQ region
North America

Markets served

NaviGate Cardiac Structures business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

NaviGate Cardiac Structures product offering

Product offering

Core offering

NaviGate Cardiac Structures develops transcatheter solutions for the treatment of tricuspid regurgitation. The company focuses on minimally invasive cardiac devices designed to address structural heart disease, specifically targeting the tricuspid valve. Its work sits within the broader transcatheter mitral and tricuspid valve market, which is projected to reach $2.49 billion by 2030 at a 9.0% CAGR.

Differentiator

Problem solved

Functional benefit

Products and services

  • Transcatheter Tricuspid Valve Solutions

Companies that use NaviGate Cardiac Structures

Customer profile

Ideal customer profiles1 record

NaviGate Cardiac Structures technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

NaviGate Cardiac Structures partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves1 record

Expansion highlights2 records

NaviGate Cardiac Structures competitors and assessment

Company assessment

Broad incumbents

  • Abbott: Diversified medical device major with the TriClip transcatheter tricuspid repair system (formerly from its acquisition of Evalve-adjacent tricuspid assets). Directly comparable as a transcatheter tricuspid competitor with deep clinical, regulatory, and commercial resources.
  • Medtronic: Major structural heart player with transcatheter valve programs across aortic, mitral, and tricuspid indications. Comparable to NaviGate as a transcatheter valve developer with significant R&D infrastructure and global commercial reach.
  • Edwards Lifesciences: Global structural heart leader developing transcatheter tricuspid platforms including the EVOQUE and PASCAL systems. Highly comparable as a transcatheter valve developer addressing tricuspid regurgitation, though operating at vastly greater scale and across many cardiovascular indications.

Emerging players

  • InnovHeart: Italian developer of transcatheter mitral and tricuspid valve replacement technologies (Saturn system). Comparable as an emerging transcatheter valve company targeting tricuspid regurgitation.
  • Cardiac Dimensions: Developer of the Carillon mitral contour system, with adjacent transcatheter tricuspid development activity. Comparable as a small-to-mid stage structural heart company developing transcatheter valve/repair technologies for under-treated indications.
  • LuxMed Systems: Early-stage developer of transcatheter tricuspid repair technology. Comparable emerging private competitor working on minimally invasive solutions for tricuspid regurgitation.

Direct peers

  • CroíValve: Dublin-based developer of a transcatheter tricuspid coaptation device for treating tricuspid regurgitation. Directly comparable niche player competing in the same transcatheter tricuspid space as NaviGate.
  • 4C Medical Technologies: Early-stage transcatheter mitral and tricuspid valve developer (e.g., AltaValve). Highly comparable as a similarly sized, venture-backed company focused on transcatheter solutions for under-served valve indications.
  • TRiCares: European developer of the Topaz transcatheter tricuspid valve replacement system. Highly comparable as a similarly focused, similarly small private competitor in the transcatheter tricuspid space.

Regional players

  • Venus Medtech: China-based structural heart company developing transcatheter valve replacement systems including tricuspid programs. Comparable as a transcatheter valve developer with overlapping technology focus, though primarily serving the China market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

NaviGate Cardiac Structures social profiles

Digital presence

NaviGate Cardiac Structures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NaviGate Cardiac Structures leadership team

Management profile

Number of profiles

Profiles2 records

NaviGate Cardiac Structures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NaviGate Cardiac Structures M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NaviGate Cardiac Structures

What does NaviGate Cardiac Structures do?

NaviGate Cardiac Structures develops transcatheter solutions for the treatment of tricuspid regurgitation. The company focuses on minimally invasive cardiac devices designed to address structural heart disease, specifically targeting the tricuspid valve. Its work sits within the broader transcatheter mitral and tricuspid valve market, which is projected to reach $2.49 billion by 2030 at a 9.0% CAGR.

When was NaviGate Cardiac Structures founded?

NaviGate Cardiac Structures was founded in 2011. It employs 11 to 50 people.

Where is NaviGate Cardiac Structures based?

NaviGate Cardiac Structures is headquartered in Lake Forest, United States, in the North America region.

Who are NaviGate Cardiac Structures's main competitors?

Broad incumbents on record are Abbott, Medtronic and Edwards Lifesciences. Emerging players are InnovHeart, Cardiac Dimensions and LuxMed Systems. Direct peers are CroíValve, 4C Medical Technologies and TRiCares. Venus Medtech is listed as a regional player.

Does NaviGate Cardiac Structures have an API?

No public API is recorded for NaviGate Cardiac Structures.

What industry is NaviGate Cardiac Structures in?

NaviGate Cardiac Structures's product category is Structural Heart Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales